Corebridge Financial’s Fate Therapeutics FATE Stock Holding History

Corebridge Financial’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-49,045	Closed	-$38.8K	–	950
2025 Q1	$38.8K	Sell	49,045 -727	-1%	-$891	﹤0.01%	2792
2024 Q4	$82.1K	Sell	49,772 -3,757	-7%	-$9.47K	﹤0.01%	2641
2024 Q3	$187K	Sell	53,529 -330	-0.6%	-$1.28K	﹤0.01%	2259
2024 Q2	$177K	Buy	+53,859	New	+$236K	﹤0.01%	2267

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Corebridge Financial's FATE Position: Q2 2025 in Review

Corebridge Financial sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 49,045 shares — an estimated $38.8K sold.

Corebridge Financial first reported a position in FATE in Q2 2024 and held it in 4 quarters. The position peaked at $187K in Q3 2024. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

Corebridge Financial reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
Corebridge Financial sold 49,045 Fate Therapeutics shares in Q2 2025, an estimated $38.8K.
Corebridge Financial first reported a position in Fate Therapeutics in Q2 2024 and held it in 4 quarters.
Corebridge Financial's Fate Therapeutics position peaked at $187K in Q3 2024.
139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.